Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 326-332 | ISSN:2251-6727

An Overview on Quality by Design in Pharmaceutical Product Development

Dr. S. Amudha*[1], Mr. Hari Shankar. R. A[1]

*[1] Associate Professor, School of Pharmacy. Sathyabama Institute of Science and Technology. Chennai, Tamil Nadu – 600119.

[1] M. Pharm Department of Pharmaceutics, School of Pharmacy. Sathyabama Institute of Science and Technology. Chennai, Tamil Nadu – 600119.

(Received: 11 November 2024 Revised: 16 December 2024 Accepted: 15 January 2025)

KEYWORDS
Pharmaceutical, enhanced, Harmony, Attributes,

ABSTRACT:

Current international regulatory thinking regarding pharmaceutical products is reflected in the Quality by Design concept. The performance of the pharmaceutical sector needs to be enhanced. More recent technology must be put into practice that can successfully lower costs while also raising the calibre of the final product. The best way to improve the quality of all pharmaceutical goods is through quality by design, or QbD. The primary goal of QbD is to guarantee the quality of the final product by combining existing knowledge with fresh estimations made during development. The International Conference on Harmony (ICH) and the Food and Drug Administration (FDA) are actively promoting QbD. The foundation of quality by design (QbD) in the pharmacy industry is knowledge of how process variables and materials impact the quality profile of finished goods. To comprehend the performance of dosage forms within the design space, this article discusses the essential components of QbD, which include the target product quality profile, critical quality attributes, risk assessment, design space, and control strategy. QbD also discusses its tools, which include process analytical technology, DoE, and quality risk management. The significance of QbD in fostering a science-based approach in the creation of pharmaceutical products is highlighted by these reviews.

INTRODUCTION:

The goal of pharmaceutical development is to create high-quality products and production processes that reliably provide the intended performance of the product. It's critical to understand that product quality cannot be evaluated. Instead of testing the end analytical process findings, quality should be incorporated into the process design. The pharmaceutical industry is regarded as one of the most heavily regulated industries, consistently producing high-quality pharmaceutical goods for human use that have pharmacotherapeutic effects to treat a variety of illnesses. The US Food and Drug Administration (FDA) released a guide for pharmaceutical companies in 2002. Businesses should incorporate efficacy, safety, and quality into their products. Today, this idea is referred to as Quality by Design. The Centre for Drug Evaluation and Research's director, Janet Woodcock, described pharmaceutical quality in a 2004 study as a product that is uncontaminated. They consistently provided the consumer with the therapeutic benefit that was advertised on the label. A new advancement in analytical methods is the QbD technique, which can be quite beneficial if used correctly.

Pharmaceutical Quality

Pharmaceutical quality is equal to f (drug ingredients, excipient production, and packaging). It must be included into the product for quality to rise. Understanding how formulation and manufacturing process variables affect product quality—function f in the equation above—was necessary to accomplish this. The Analytical and Quality by Design approach was used to create and evaluate RP-HPLC/LC techniques. Customer satisfaction with regard to service, product, and procedure is what quality is all about. The client expects flawless quality, dependability, affordability, and prompt delivery. Value, cycle, time, cost, productivity, and quality are all interconnected. Effective planning is

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(1), 326-332 | ISSN:2251-6727

necessary to ensure that the product and service are of high quality. As the QbD idea is developed, "pharmaceutical quality regulation will undergo a considerable transformation, from an empirical procedure to a risk-based, more scientific method. Additionally, QbD aids in developing the strategy and common language required to forge the connection required for outsourcing to be successful. Originally, the four-step QbD approach was presented for industrial operations.

- Identifying the Quality Target Product Profile (QTPP), which is a measure of patient requirements.
- The manufacturing process is designed and developed, the manufacturing.
- Design Space (DS) is defined, and risks are assessed.
- Putting a Control Strategy into Practice.

The qualities of the product are influenced by formulation factors, or independent variables, which are helpful in optimising independent variables to track the behaviour of dependent variables in generating the best possible product under the specified circumstances. Therefore, QbD incorporates variables to facilitate the ultimate optimal medication formulation. With a limited number of tests, QbD is used to optimise experimental circumstances in order to determine the most appropriate conditions.

Understanding Pharmaceutical QbD

Quality: According to the ICH Q8 standard, Quality by Design(QbD) is a regular approach to development that starts with destined pretensions. and places a strong emphasis on process control and product and process understanding, predicated in sound wisdom and quality threat operation. The United States Food and Drug Administration's trouble to guarantee product quality throughout the entire process set up in pharmaceutical development of colourful lozenge forms. It's pivotal for all products, including biotech and generics.

Purpose and Objectives: To promote creativity and effectiveness in product development, QbD promotes process and product understanding. also, Using a QbD system aids in FDA compliance. The advantages of QbD can be realised in lower charges and waste as well as faster product development. Custom 3D published prostheses made using the quality by design (QbD) methodology can help guarantee that goods are created and produced directly and error-free from the launch**.**

The FDA publication defined QbD as:

1. Developing a product to meet predefined product quality, safety, and efficacy.
2. Designing a manufacturing process to meet predefined product quality, safety and efficacy.

FDA accepted this concept in 2004 and detailed description was given in pharmaceutical cGMPs for the 21st century-

- A Risk-Based: The FDA has taken the initiative to guide the pharmaceutical industry on implementing the concept of QbD into its process.
- FDA's Process Validation: Guidance in Jan 2011 is for companies to continue benefiting from knowledge gained and continually improve throughout the process lifecycle by making adaptations to assure root causes of manufacturing problems are addressed.

International Conference on Harmonization (ICH):

Relevant documents from the international conference on harmonization of the technical requirement for registration of pharmaceuticals for human use. (ICH). US FDA / EMA refers to ICH guidelines Q8, Q9, Q10, Q11 & Q12 for QbD implementation.

- Pharmaceutical Development Q8 (R2).
- Quality Risk Management Q9.
- Pharmaceutical Quality System Q10**.**

ICH Q8: In the previous decade, the US FDA announced a new pharmaceutical regulatory concept, quality by design (QbD), which has challenged the pharmaceutical industry to design the quality of the final product instead of testing the product. The ICH guideline Q8 definition for QbD is "A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.

Components of Drug Product Given by ICH Q8

The biological and physicochemical characteristics of the medicinal ingredients that may affect how well the drug product works and its capacity to be manufactured.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 326-332 | ISSN:2251-6727

Example of physicochemical and biological properties includes:

- Solubility.
- Water content.
- Particle size.
- Excipients.

It is important to assess how well the medication ingredients work with the excipients. When it comes to goods that include multiple psychoactive substances, the Additionally, the drug compounds' compatibility with one another should be assessed.

Formulation Development: Finding the qualities that are essential to the drug product's quality and emphasising the development of the formulation design are two aspects of formulation development. from the original idea to the finished design. Clinical formulations and the suggested commercial formulation are linked by comparative in-vitro studies, such as Dissolution, or in-vivo studies, such as BE**.**

Container and Closure System

There should be justification for the materials used for both primary and secondary packaging. It is important to take into account any potential interactions between the product and the label or container.

ICH Q9:

It offers broad recommendations and sources for a few of the main instruments used in risk assessment. Industry examples are given. and regulators to assess the risk to patient safety and quality based on scientific understanding. As a component of an efficient quality system, quality risk management aids in determining the likelihood and seriousness of the risk.

It offers the following non-exhaustive list of typical risk management tools: Simple techniques for facilitating risk management, like as check sheets, flowcharts, and the Ishikawa fishbone diagram.

- Analysing fault trees and ranking and filtering risks.
- Initial danger assessment.
- Critical control points and hazard analysis.
- Analysis of failure mode and repercussions.

ICH Q10:

Pharmaceutical Quality Systems provide an abstract explanation of how Quality by Design works to guarantee the quality of pharmaceutical products. Particularly for ANDA sponsors, who did not participate actively in the 18 ICH procedures. These guidelines are applicable throughout the product lifecycle and aid in the design, development, and manufacture of drug substances, including APIs, and drug products, including biotechnology and biological products.

Quality Attributes Governing Quality of Desired Product



Regulatory Challenges and Inspection

The regulatory load is reduced with a QbD approach since there are more product-based ranges and limitations. process comprehension. Prior clearance is not necessary for changes made within these ranges and limitations. Inspections of approved biological therapeutical drug products have historically been carried out in line with CDER's compliance program and following the FDA system-based methodology. Under a QbD concept, the FDA inspection team will evaluate the process design's implementation and efficacy during prelicense and preapproval inspections. The inspection will assess the efficacy of the quality system in terms of process improvement, control procedure modifications, and consistent product quality. Businesses Wanted FDA clarification on authorised practices, criteria for choosing and rejecting Critical Quality Attributes, standards to ensure the sufficiency of criteria and controls for the analytical approach replacement.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 326-332 | ISSN:2251-6727

Benefits of Implementing QbD for FDA.

Boost manufacturing productivity while cutting expenses, project rejections, and waste.

In CDER's generic drug office, a Question-based review (QbD) procedure has been put into place.

The process of applying QbD to a biological licence application (BLA) is moving forward.

Quality by Design was used for optimisation design as a full factorial design. Learning within an organisation is an investment in the future.

Seven Steps of QbD:

The most effective method for determining how to apply QbD in your company is to follow this easy seven-step procedure:

- Employ a self-employed quality design specialist.
- With the help of an expert doing a gap analysis, audit your company and procedures.
- All of your staff should participate in a basic QbD session, which should be led by an expert and tailored to speak to various levels, from the boardroom to the factory floor.
- Examine the expert's report and suggestions.
- Create a plan for implementation that includes budgetary estimates and timelines.
- Distribute the resources.
- Keep the independence specialist on board as your advisor for project assurance.

Quality Target Product Profile (QTPP):

QTPP is defined by ICH Q8 as "A prospective description of a medicinal product's quality features that Ideally, the intended quality will be attained while considering the medication product's safety and effectiveness.

- Characteristics of quality: purity and sterility.
- Dissolution is a pharmacokinetic property.
- therapeutic outcome
- Neonates are the target patient population for clinical diagnosis.
- Temperature, light levels, etc. that affect shelf life.

Following the identification of QTPP, the following action is performed Find the pertinent CQAs. A CQA is characterised as a physical, chemical, biological, or microbiological attribute that falls within a suitable range, limit, or distribution to guarantee the intended level of product quality.

The comprehensive identification of the QTPP is always necessary for the effective completion of a product development exercise in order to achieve the end goals. Quality risk management and experimentation to ascertain the impact of variation on product quality are used to identify Critical Quality Attributes [CQAs]. Finding the CQA creates the basis for the product design and process comprehension.

Target Product Profile (TPP)

The FDA provides instructions for creating a Target Product Profile (TPP). in accordance with these rules. The TPP has a complete correlation with drug development programs that offer insights on the medicine's development. In general, the TPP helps establish a connection between medication development and labelling. "Recognition of critical quality attributes of the drug product with consideration of its intended use as well as the route of administration hence it becomes essential to consider the intended usage and route of administration," states ICH-Q8 (pharmaceutical development).

Critical Material Attributes (CMA)

CQA is a quality attribute that includes physical, chemical, biological, or microbiological components, according to ICH. features, and it is intended that these features be managed (either directly or indirectly) to provide confidence that the final product will achieve the required levels of performance, stability, safety, and efficacy. .

The crucial components that have a direct impact on the CQAs are the CMAs. These are described as an input material's physical, chemical, biological, or microbiological feature or characteristic that must fall within a suitable range, limit, or distribution in order to guarantee the intended level of quality in drug products. When assessing the performance of a product, CQA looks at mechanistic factors including particle size and hardness. Therefore, TPQP could be used to explain both the product performance and the factors that influence it.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 326-332 | ISSN:2251-6727

Design Space:

The set of all possible combinations of a method's input variables that have been shown to ensure the quality of the information generated by the technique. One unit operation, several, or the complete process can all have their own design area. To determine the criticality of factors and their ranges for creating a design space, the risk assessment, previous experiments, and multivariate factor screening techniques are employed. A pharmaceutical product may have more than one design space. Ideally, design space is created through experimental design at the lab/pilot scale and then extrapolated to the exhibit/commercial scale by leveraging scale-independent factors to establish a correlation.

Control Strategy:

Control over the input's CMA is part of a control strategy built on in-depth knowledge of the process and the final output. materials and intermediates, process parameter control, the quality of the finished drug product, and the final packaging. All of these control plan elements fall under the purview of process analytical technology. Control space, which is an upper and lower limit for raw materials (or) a process where parameters and material are frequently controlled to ensure the quality of the product, should be included in the design space.

Currently, every process has a control strategy. By regulating the active ingredient production process, testing raw materials, and carrying out the medication product, this system guarantees the quality of the final product. production procedure as outlined in a set batch record, end-product testing, and in-process material testing. A risk factor that has been identified needs to be managed.

Tools of QbD

Quality risk management (QRM):

According to the FDA, risk management is a strategic safety program that uses intervention to lower product risk. instruments. It is a methodical procedure for evaluating, managing, and reviewing risks to the drug's quality throughout its life cycle. The quality unit, regulatory affairs, production operations, sales and marketing, and clinical department all share responsibilities for risk management. This document emphasized two key ideas for the application of quality risk management. The assessment of quality risk should be grounded in scientific understanding and ultimately connected to patient safety.

The degree of risk should be reflected in the formality, documentation, and effort required in the quality risk management process.

Design of experiment (DoE):

An orderly, systematic approach to figuring out how variables influencing a process relate to the result "Design of Experiments" is the name given to the procedure. We may specify a lot of factors, build models, define responses, assess the models, understand the results, and ultimately make a decision with the aid of DoE. We are accustomed to studying a single variety in the past. DoE aids in multivariate analysis, including wavelength, flow rate, concentration, and its effects on retention time, resolution, and other factors in the case of HPLC. One such organized approach that takes into account how the CMAs and CPPs affect the CQAs of the final dose form is experiment design. Since the FDA introduced QbD to the formulation and development of pharmaceuticals, it has attracted a lot of interest.

PAT as an Important Tool of QbD:

The definition of PAT is "Systems and tools that use real-time measurements, or quick measurements during processing, of changing in-process material quality and performance characteristics to offer data to guarantee ideal processing to generate a finished product that continuously satisfies set requirements for quality and performance. PAT is a component of the quality by design (QbD) approach, which offers resources to support quality.

CONCLUSION:

Quality by Design, or QbD, is a technique that is becoming more and more significant and popular in pharmaceutical products. progress. improves production and gives patients access to high-quality medications. The requirements of the contemporary production process are indicated by Quality by Design (QbD) and its instruments. Designing and manufacturing with quality in mind saves money and time. Additionally, QbD has a broad range of applications in biotechnological goods, including monoclonal antibodies, enzymes, and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 326-332 | ISSN:2251-6727

vaccines. More regulatory flexibility in the future is possible because to this new Quality by Design (QbD) process. Furthermore, Quality by Design is now a widely used manufacturing paradigm that extends well beyond the pharmaceutical industry.

Reference:

1. ICH Harmonised Tripartite Guideline Pharmaceutical Development Q8 (R2) current step 4 version dated 2009 August.
2. James Swarbrick: Quality target product profile (QTPP) for Pharmaceutical packaging and delivery systems. Encyclopedia of Pharmaceutical Science and Technology, CRC Press Taylor & Francis Group 2013; 4(4).
3. International Conference on Harmonization (ICH). Guidance for industry: Q9 quality risk management, ICH Harmonized Tripartite Guideline 2005; 4.
4. FDA CDER Draft guidance for industry. Pharmaceutical Quality System 2007.
5. Lionberger RA, Lee LS, Lee L, Raw A and YU LX: Quality by design: concept for ANDAs. The American Association of Pharmaceutical Scientist 2008; 10: 268-76. 20. Nasr M. Risk – based CMC review paradigm, Advisory committee for pharmaceutical science meeting 2004.
6. Jain S: Quality by Design (QbD): A comprehensive understanding of implementation and challenges in pharmaceutical development. Indian Journal of Pharmaceutical Sciences 2013; 6: 29-35.
7. Dra Kulich: A Critical Challenges to implementing QbD: AQ&A with FDA. Pharm Technol 2009; 33: 90-4.
8. Mimansha Patel: Review article: Quality by Design (QbD). Indo American Journal of Pharmaceutical Research 2018; 8(11): 1357-60.
9. Satish K. Mandlik: I mplementation of Quality by Design (QBD) approach in formulation and Development of Ritonavir Pellets using Extrusion Spheronization method. International J of Applied Pharma 2020; 12(1): 139 –146.
10. Mayur Ashok Chordiya, Hemant Hiraman Gangurde and Vikram Nirmal Sancheti: Quality by design: A Roadmap for quality pharmaceutical products. Journal of Reports in Pharmaceutical Science 2019; 8(2): 289-94.
11. Roshni Vora and Yamini Shah: Investigation of Quality target process parameters (QTPP) and Critical Material Attributes (CMA) of Nanocellulose as a potential Excipient. Inter J of Applied Pharma 2019; 11(4): 386–95. 2
12. Bhavani PG and Akila Devi DA: Development and validation of stability indicating uplc method for the simultaneous estimation of drugs in combined dosage forms using quality by design approach. Asian J Pharm Ana 2020; 10(3): 158-164.
13. Namjoshi S, Dabbaghi M, Roberts MS, Grice JE and Mohammed Y: Quality by design: development of the quality target product profile (qtpp) for semisolid topical products. Pharmaceutics 2020; 12(3): 287.
14. Singh B: Quality by Design (QbD) for holistic pharma excellence and regulatory compliance. Pharma Times 2014; 46(8): 26-3.
15. Gandhi A and Roy C: Quality by Design (QbD) in Pharmaceutical Industry: Tools, Perspectives and Challenges. Pharma Tutor 2016; 4(11): 12-20.
16. Beg S, Rahman M and Kohli K: Quality-by-design approach as a systematic tool for the development of nano pharmaceutical products. Drug Discovery Today 2019; 24(3): 717-25.
17. Trevor Murphy, Niall O Mahony, Krishna Panduru, Daniel Riordan and Joseph Walsh: Pharmaceutical manufacturing and the quality by design (QBD), process analytical technology (PAT) approach. 27th Irish Signals and Systems Conference 2016; 1-7.
18. Sarwar Beg and Saquib Hasnain: Pharmaceutical Quality by Design: Principles and Applications. https://www.journals.elsevier.com/arabian-journal-ofchemistry .2019 March 29:448.
19. Lan Zhang and Shirui Mao: Application of Quality by Design in the current drug development. Asian Journal of Pharmaceutical Sciences 2017; 12(1): 1-8.
20. Kamboj: Quality by Design (QbD) in Pharmaceutical Industry. International Journal of Current Pharmaceutical Research 2015; 6(2): 142-8.
21. Borman P. Chatfield, M. Nethercote, P Thompson and Truman K: The application of quality by design to analytical methods. Pharmaceutical Technology 2007; 31: 142-52.

22. Sandipan R: Quality by design: a holistic concept of building quality in pharmaceuticals. International Journal of Pharmacy and Biomed Research 2012; 3(2): 100- 8.
23. Somana Siva Prasad, Venkateswara Rao Anna and Bikshal Babu Kasimala: Quality by Design (QbD) based development and validation of an HPLC method for the estimation of Lurasidone in Pharmaceutical formulation. Journal of Critical Review 2020; 7(18): 2155–61.
24. International Conference on Harmonization (ICH). Guidence for Industry Q8 (R2) Pharmaceutical development, ICH harmonized tripartite guidelines, step 4; 2009.
25. Ana Simoes, Francisco Veiga, Carla Vitorino and Ana Figueiras: A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach. Journal of Pharmaceutical Sciences xxx 2018; 1-10.
26. Daniel Martinez-Marquez, Ali Mirnajafizadeh, Christopher P. Carty and Rodney A: Stewart: Application of quality by design for 3D printed bone prostheses and scaffolds s. PLoS ONE 2018; 12: 13(4).
27. Kovács A, Berkó S, Csányi E and Csóka I: Development of nanostructured lipid carries containing salicylic acid for dermal use based on the quality by design method. European J of Pharmaceutical Sciences 2017; 99: 246-57.
28. Valenzuela-Oses JK, García MC, Feitosa VA, Pachioni Vasconcelos JA, Gomes-Filho SM, Lourenço FR, Cerize NNP, Bassères DS and Rangel-Yagui CO: Development and characterization of miltefosine-loaed polymeric micelles for cancer treatment. Materials Science and Engineering 2017; 81: 327-33.
29. Badawi MA and El-Khordagui LK: A Quality by Design approach to optimization of emulsions for electrospinning using factorial and D-optimal designs. European Journal of Pharmaceutical Science 2014; 58: 44-54.